Latest Infinity Pharmaceuticals Stories

Infinity Pharmaceuticals, a cancer drug discovery and development company, has announced that it has met pre-specified criteria to expand both arms of its ongoing Phase II clinical trial evaluating IPI-504, its lead heat shock protein 90 inhibitor, in patients with advanced non-small cell lung cancer. The study is designed to evaluate IPI-504 as a monotherapy in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) whose tumors have relapsed or become refractory to prior treatment...

Infinity Pharmaceuticals, a cancer drug discovery and development company, has announced preclinical data demonstrating anti-tumor activity with IPI-493, the company's oral heat shock protein 90 inhibitor. In preclinical studies, IPI-493 potently inhibits heat shock protein 90 (Hsp90) and has strong pharmaceutical properties in vitro and in vivo, including selectivity for cancer cells over normal cells, as well as high oral bioavailability, the company said. Moreover, IPI-493 showed...

Infinity Pharmaceuticals has initiated a Phase I clinical trial of IPI-493, its oral anti-chaperone agent, in patients with advanced solid tumors. The multi-center, Phase I study of oral IPI-493 is designed as a dose-escalation trial in patients with advanced solid tumors. The primary objectives of the study are to assess safety and tolerability and to identify a treatment regimen for subsequent studies of IPI-493. Anti-tumor activity of IPI-493 will be measured using computed tomography...